October 8, 2010 - The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a public-private partnership that began in October, 2004 as a landmark study to find more sensitive and accurate methods to detect Alzheimer’s disease (AD) at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. The original goal of ADNI was to define biomarkers for use in clinical trials to determine the best way to measure treatment effects of AD. However, as the field has evolved, the goal has been expanded to include the use of biomarkers to detect AD at a pre-dementia stage.
ADNI involves scientists at 59 research centers – 54 in the U.S. and five in Canada. Currently the study involves over 800 study participants comprised of 200 with AD, 400 with mild cognitive impairment (MCI) and 200 with normal cognition. In 2010, funded by the federal stimulus package, the ADNI study will continue through “ADNI GO,” sponsored by the National Institute on Aging (NIA) at the National Institutes of Health (NIH
Specifically, researchers are looking for volunteers between the ages of 55 and 90 who may be transitioning from normal cognitive aging to an early stage of mild cognitive impairment (MCI), a condition that may progress to Alzheimer’s disease or other forms of dementia. This two-year, $24 million study focuses for the first time on people experiencing the very earliest complaints of memory problems that affect their daily activities. ADNI GO expands on the groundbreaking Alzheimer’s Disease Neuroimaging Initiative (ADNI), the largest and most comprehensive study of its kind to date, and will continue efforts to identify biomarkers that can help build a greater understanding of the progression of AD.
More information about the study is available at the Alzheimer's Disease Cooperative Study website.